How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Blood Glucose Testing Device Market
- By Product Type: Self-Monitoring Blood Glucose (SMBG) Devices, Continuous Glucose Monitoring (CGM) Systems, Flash Glucose Monitoring Systems, Non-Invasive Glucose Monitoring Devices
- By End User: Hospitals and Clinics, Home Care Settings, Diagnostic Laboratories, Ambulatory Surgical Centers
- By Technology: Electrochemical Biosensors, Optical Sensors, Enzymatic Sensors, Microfluidic Sensors
- By Application: Diabetes Management, Clinical Research, Hospital Patient Monitoring, Fitness and Wellness Monitoring
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Retail, Direct Sales
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Self-Monitoring Blood Glucose (SMBG) Devices leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Blood Glucose Testing Device Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 4
End User 4
Technology 4
Application 4
Distribution Channel 4
Companies profiled
Abbott Laboratories
Roche Diagnostics
Ascensia Diabetes Care
LifeScan (a Johnson & Johnson company)
Dexcom Inc.
Medtronic plc
Bayer AG
Nipro Corporation
Arkray Inc.
Sinocare Inc.
Terumo Corporation
A. Menarini Diagnostics
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Ascensia Diabetes Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →LifeScan (a Johnson & Johnson company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Dexcom Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bayer AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Nipro Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Arkray Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sinocare Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →A. Menarini Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Nova Biomedical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Trividia Health Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Beijing Choice Electronic Technology Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$2,971M by 2033 · 9.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Self-Monitoring Blood Glucose (SMBG) Devices56.5
- Continuous Glucose Monitoring (CGM) Systems16.0
- Flash Glucose Monitoring Systems9.2
- Non-Invasive Glucose Monitoring Devices18.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$472.9M → $943.2M · 9.0%
Europe$329.6M → $651.1M · 8.9%
Asia Pacific$300.9M → $576.1M · 8.5%
Latin America$186.3M → $408.4M · 10.3%
Middle East and Africa$143.3M → $293.4M · 9.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.502026
9.502027
9.512028
9.522029
9.542030
9.552031
9.572032
9.592033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories14.8
- Roche Diagnostics23.7
- Ascensia Diabetes Care10.1
- LifeScan (a Johnson & Johnson company)6.3
- Dexcom Inc.6.9
- Medtronic plc10.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type16.7%
End User13.8%
Technology23.2%
Application14.9%
Distribution Channel31.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe22.7
- Asia Pacific20.1
- Latin America14.2
- Middle East and Africa10.2
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 76 | 92 | 86 | 92 | 92 | 82 | 87 |
| Roche Diagnostics | 83 | 83 | 78 | 72 | 86 | 85 | 81 |
| Ascensia Diabetes Care | 85 | 84 | 75 | 65 | 65 | 67 | 74 |
| LifeScan (a Johnson & Johnson company) | 76 | 62 | 69 | 59 | 75 | 60 | 67 |
| Dexcom Inc. | 76 | 74 | 71 | 58 | 52 | 59 | 65 |
| Medtronic plc | 51 | 69 | 67 | 68 | 61 | 53 | 62 |
| Bayer AG | 64 | 63 | 52 | 60 | 53 | 54 | 58 |
| Nipro Corporation | 40 | 39 | 51 | 55 | 35 | 55 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Roche Diagnostics
- Ascensia Diabetes Care
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Roche Diagnostics | ◐ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Ascensia Diabetes Care | ✓ | ✓ | ◐ | − | − | ✓ |
| LifeScan (a Johnson & Johnson company) | ◐ | ✓ | ✓ | ◐ | ✓ | − |
| Dexcom Inc. | ✓ | ✓ | ◐ | − | − | − |
| Medtronic plc | − | − | − | − | ◐ | − |
| Bayer AG | ◐ | ◐ | ◐ | ◐ | − | − |
| Nipro Corporation | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories87
2Roche Diagnostics81
3Ascensia Diabetes Care74
4LifeScan (a Johnson & Johnson company)67
5Dexcom Inc.65
6Medtronic plc62
7Bayer AG58
8Nipro Corporation46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesRoche Diagnostics
Challenger2
Strong scale, closing on the leaders.
Ascensia Diabetes CareLifeScan (a Johnson & Johnson company)
Contender3
Focused players with pockets of strength.
Dexcom Inc.Medtronic plcBayer AG
Niche1
Specialists in a single segment or region.
Nipro Corporation
Go-to-market strategy
Land Product Type in North America, then scale across Blood Glucose Testing Device Market — a $506M beachhead inside a $8.79B market.
Beachhead (SOM)$506Mobtainable near-term
Serviceable (SAM)$3.35Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Self-Monitoring Blood Glucose (SMBG) Devices
Best fit — highest urgency & budget in Product Type.
Economic buyer81 fit
Continuous Glucose Monitoring (CGM) Systems
Strong fit — clear ROI and a fast path to value.
End user68 fit
Flash Glucose Monitoring Systems
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blood Glucose Testing Device Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation13%
Closed-won6%
$14.5KCAC
$56KLTV
3.9:1LTV : CAC
< 3 moCAC payback
Investment thesis
Blood Glucose Testing Device Market is a resilient opportunity — $6.98B by 2033, compounding at 3.3%.
TAM · 2025$5.40Btoday
TAM · 2033$6.98Bforecast
CAGR3.3%2027–2033
Cumulative$55.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.98BTotal addressable market
SAM$2.49BServiceable available market
SOM$539MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.3% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.98BLarge & growingTAM by 2033 at 3.3% CAGR
$2.49BServiceable nowreachable with today’s model
$539MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.44BBear2.1% CAGR
$6.98BBase3.3% CAGR
$8.93BBull4.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Blood Glucose Testing Device Market — a $5.78B market by 2033. Plan: grow share from 10.4% to 17.3%.
Market size · 2033$5.78Btotal addressable
Market CAGR8.0%2027–2033
Target share17.3%from 10.4% today
Revenue ambition$1,000Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.4% | 17.3% | Behind |
| Revenue | $622M | $1,000M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 33.7% | 40.6% | On track |
| Customer retention | 90.5% | 95.3% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $137M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Sales deck · value proposition
Win the Blood Glucose Testing Device Market conversation — a $5.94B market you can size, segment and defend in minutes.
Market size · 2033$5.94Btotal opportunity
Growth9.2%CAGR to 2033
Addressable buyers1,577+accounts in scope
Typical ROI7.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.2×return on cost, year one
< 2 mopayback period
$83K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Abbott LaboratoriesRoche DiagnosticsAscensia Diabetes CareLifeScan (a Johnson & Johnson company)Dexcom Inc.Medtronic plcBayer AGNipro Corporation+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blood Glucose Testing Device Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blood Glucose Testing Device Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Blood Glucose Testing System Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportBlood Glucose Therapy System Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportBlood Lancets Market
Market size, share, segmentation and regional forecast.
$514M market · 2025 base year
View reportBlood Lipid Meter Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportBlood Management Labels Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportBlood Meal for Poultry Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportBlood Meal, Meat and Bone Meal (MBM) Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportBlood Monitoring & Cardiac Monitoring Devices Market
Market size, share, segmentation and regional forecast.
$842M market · 2025 base year
View reportBlood Monitoring Device Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportBlood Orange Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportBlood Oxygen Measurement Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportBlood Plasma Fibrinogen Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.